The latest on the German healthcare industry’s main sectors
The Export Initiative for the German Healthcare Industry – HEALTH MADE IN GERMANY – has updated its profiles of the country’s main medical sectors. The guides contain new figures, analyze the latest trends, and look at the impact of the Coronavirus pandemic.
The four brochures are available for download from the initiative’s website. In addition to the latest statistics, the profiles are chock full of information on sector structure, innovation, and present what makes German pharmaceuticals, medical technology, medical biotechnology and digital health products and services among the world’s best. What is more, the profiles provide insight into each field with interviews from company leaders and intros for key sector organizations.
HEALTH MADE IN GERMANY. The Medical Biotechnology Sector recounts how this industry rose to the challenge of COVID-19 to make Germany leader in developing a novel messenger RNA-based vaccine. Beyond the story of Pfizer/BioNTech, the analysis describes the factors driving growth in the sector that gave it EUR 6.7 billion in turnovers in 2020. The brochure also explains how medical biotech is accounting for an increasing share of total pharmaceuticals revenues.
COVID-19 had a major effect on innovative medical IT as well, as is presented in HEALTH MADE IN GERMANY. The Digital Health Sector. The brochure tells how the pandemic accelerated developments in digital health by increasing the need for remote patient-physician consultations, for example. It also gives insight into how the sector benefits from a dynamic start-up ecosystem, exceptional research and medical facilities, and solid government support.
HEALTH MADE IN GERMANY. The Medical Technology Sector focuses, among other things, on the resilience of Germany’s medtech sector through the pandemic. In 2020, the industry generated EUR 34.2 billion in total sales, with export revenues accounting for around two-thirds of that figure. Furthermore, more than a third of total turnover continues to be generated by products that were three years old or less.
And last but not least, Germany’s globally-renowned pharmaceutical sector is covered in HEALTH MADE IN GERMANY. The Pharmaceutical Sector. In terms of turnover – EUR 42.5 billion in 2020 – the industry association BPI ranked Germany the European leader in 2021. Beyond that, between 2017 and 2020, the annual growth rate recorded by the country’s pharmaceutical companies was 10 percent.
To explain German-pharma’s success, Dr. Markus Rudolph, the CEO of InfectoPharm Arzneimittel, said, “Outstanding enterprises – such as Bayer, Merck, and Boehringer – demonstrate that Germany offers attractive conditions for growth. This also applies to a large number of midsized, family-led companies like InfectoPharm. … They operate at the heart of Europe, are embedded into global supply chains, and enjoy close proximity to excellent research facilities.”